Non-invasive bladder urothelial carcinoma

This pilot study tested a drug called BGJ398 in 4 people with a type of bladder cancer that stays in the bladder lining but keeps coming back after standard treatment. The drug targets tumors with a specific genetic change (FGFR3 mutation or fusion). The main goal was to see if t…

This trial tests whether giving the chemotherapy drug mitomycin C into the bladder just before tumor removal works better than giving it right after. The goal is to reduce the chance that non-muscle-invasive bladder tumors come back. Adults with one or two bladder tumors will be …

This early-phase trial tested two drugs—durvalumab and vicineum—in 15 people with high-grade non-muscle-invasive bladder cancer that had not responded to standard BCG treatment. The goal was to see if the combination is safe and can help the immune system fight the cancer. Partic…

This study compared two surgical techniques for removing early-stage bladder tumors: a new laser method (holmium laser en-bloc resection) and the standard approach (conventional transurethral resection). 100 adults with suspected non-muscle-invasive bladder cancer were randomly a…

This study tested a new treatment called VG161, a virus designed to attack cancer cells, in 20 people with a type of bladder cancer that didn't respond to standard therapy. The virus was given directly into the bladder through a tube. The goal was to see if it is safe and if it c…

This study tested whether giving a short, intensive course of the chemotherapy drug Mitomycin C before surgery (chemoresection) could lower the chance of bladder cancer coming back, compared to the usual approach of surgery followed by regular chemotherapy instillations into the …

This study compares two surgical methods for removing non-muscle invasive bladder tumors. The new method removes the tumor in one piece, while the standard method removes it in fragments. Researchers want to see if the one-piece approach leads to better tumor removal and fewer re…

This study tested two surgical methods for removing early-stage bladder tumors that haven't spread to muscle. One method removes the tumor in one piece (en bloc), while the standard method removes it in multiple pieces. Researchers wanted to see if the one-piece method gives bett…

This early-phase trial tested a new drug called UGN-301 (zalifrelimab) given directly into the bladder for people with recurrent non-muscle invasive bladder cancer. The study included 51 participants and aimed to check safety and find the right dose, both alone and with other dru…

This study looked at 150 people who had surgery for early-stage bladder cancer. After surgery, they received one of three different fluids (distilled water, normal saline, or hypertonic saline) to wash the bladder. The goal was to see if any fluid was better at preventing the can…

This phase 2 trial tested pemigatinib, a daily pill that blocks certain growth signals, in 30 people with recurrent low- or intermediate-risk non-muscle invasive bladder cancer. Participants took the drug for 4-6 weeks before their standard surgery to remove bladder tumors. The m…

This study asked 107 people with a history of non-muscle invasive bladder cancer whether they preferred a non-invasive urine test (CxBladder Monitor) or the standard cystoscopy (a thin tube inserted into the bladder) for routine cancer surveillance. Participants tried both method…

This early-phase study tested a new imaging agent called 89Zr-girentuximab in 6 people with non-muscle-invasive bladder cancer. The goal was to see if it could safely and clearly show tumors on PET/CT scans. Researchers looked for uptake spots in the bladder and checked for side …

Researchers are investigating whether a patient's age influences the outcomes of BCG therapy for a high-risk form of bladder cancer called pT1 high-grade. This study reviews medical records from 64 patients who received standard BCG treatment after tumor removal. The goal is to c…

This study investigates whether the amount of urine left in the bladder after urination (post-void residual) influences the return or worsening of non-muscle invasive bladder cancer. Researchers will follow 500 patients who have had surgery to remove bladder tumors, measuring res…

This study looked at whether three proteins (E-cadherin, β-catenin, and SOX4) can help predict if non-muscle invasive bladder cancer will return or get worse after surgery. Researchers examined tissue samples from 30 patients who had bladder tumor removal. The goal was to see if …

This study tested whether doing a second surgery soon after the first helps manage high-risk non-muscle invasive bladder cancer. 70 patients who had an initial tumor removal got an early second look procedure. The goal was to see if any cancer remained and what factors affected t…

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…